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We report a case of chromoblastomycosis in lesions on the chest and foot. Itraconazole was chosen as the initial
treatment for this patient, who was followed up for 8 months before becoming noncompliant. The pathogenic
fungal species was identiﬁed as Rhinocladiella similis by ITS region sequencing. In vitro analyses indicate that the
fungus was sensitive to posaconazole and itraconazole. This report presents R. similis as a new agent of
chromoblastomycosis and raises the hypothesis that this species could be more resistant to some antifungals than
R. aquaspersa.
1. Introduction
Chromoblastomycosis is a tropical and subtropical skin disease
caused by environmental accidental inoculation of pathogenic fungi.
For instance, this disease often aﬀects farmers, and it is believed that
the fungus penetrates the skin through injuries caused by contaminated
environmental debris [1,2]. Chromoblastomycosis is a chronic granu-
lomatous infection characterized by muriform cells, tissue proliferation,
and microabscess, which may cause several complications to the health
of aﬀected individuals [1], including the inability to work if not treated
in the early stages. This fungal skin infection is characterized as one of
the Neglected Tropical Diseases (NTD) [2], a cover term for a group of
ignored infectious diseases aﬀecting the poorest regions in the world
[3].
Rhinocladiella is a genus of melanized fungi that can cause chromo-
blastomycosis. Taxonomically, the Rhinocladiella genus belongs to the
Chaetothyriales order (Ascomycota). This order contains several clini-
cally relevant species of the genera Exophialia, Cladophialophora,
Fonsecaea, and Phialophora, which are possible etiologic agents of
chromoblastomycosis and/or phaeohyphomycosis [1,2,4,5]. Rhinocla-
diella similis was isolated for the ﬁrst time in a human ulcerated foot
lesion characterized as chromoblastomycosis, whose report was pub-
lished in a congress abstract book M.A. Resende, R.B. Caligiorne, C.R.
Aguilar and M.M. Gontijo, Abstr. 14th Congr. Int. Soc. Human Anim.
Mycol., p. 274, 2000 [4]. Later, R. similis was isolated from environ-
mental samples [6], such as hemodialysis water [7], tap water and
groundwater [8]. We, therefore, herein report the ﬁrst case published in
a scientiﬁc journal and the second case published in the worldwide
literature of R. similis causing chromoblastomycosis.
2. Case
In 2002, a 47-year-old, Mexican rural worker male patient pre-
sented asymptomatic scaly lesions on the dorsum of the left foot and on
the chest. According to the patient, these manifestations had started 4
years before the physician oﬃce visit. The ﬁrst lesion appearances were
characterized as small plaques on the foot, and then later lesions arose
on the chest. The patient also declared having no history of traumatic
injury in these regions. Upon examination, several erythematous
verrucous plaques were seen on both chest and foot (Fig. 1A).
In the same day of his ﬁrst presence in hospital, direct and culture
microscopic examinations were performed. Direct microscopic exam-
ination of plaques with KOH (20%) revealed muriform cells (5–7 µm in
diameter; Fig. 1B) characterizing a chromoblastomycosis and the oral
treatment with itraconazole (200 mg/day) was started immediately.
Cultures were performed in Sabouraud dextrose agar (Difco, USA)
supplemented with chloramphenicol (0.5 mg/mL) and incubated at
30 °C for 14 days. Both macroscopic (Fig. 1C) and microscopic analyses
supported the identiﬁcation of Rhinocladiella sp. colonies.
The patient was followed up during 8 months, and lesion improve-
ment was observed despite his intermittent noncompliance. After this
period, the patient quit the treatment. Thirty two months after his ﬁrst
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visit, the patient reappeared presenting active lesions in the same
places, but he did not want to restart the treatment and did not return to
further consultation.
For fourteen years the isolate was maintained in bank collection of
fungal in Mexico laboratory. In Brazilian laboratory, the identiﬁcation
at level species was performed with its grown for 14 days in Sabouraud
broth at 30 °C, without shaking. Total genomic DNA was extracted and
puriﬁed from cultures using the Power Soil DNA Isolation Kit (Mobio,
USA). Sequencing of the ITS1-5.8S rDNA-ITS2 region was performed
using the universal primers ITS1 and ITS4. The ampliﬁcation conditions
were: initial denaturation at 94 °C for 5 min, 30 cycles of denaturation
at 94 °C for 1 min, annealing at 55 °C for 1 min, extension at 72 °C for
2 min, and ﬁnal extension at 72 °C for 10 min [5]. The PCR product was
puriﬁed using ExoSAP-IT (Aﬀymetrix, USA) and sequenced in the ABI-
PRISM 3100 Genetic Analyzer (Applied Biosystems), according to the
manufacturer's instructions. The sequence was assembled and com-
pared with sequences of type strains reported in GenBank using the
Basic Local Alignment Search Tool (BLAST) algorithm. The etiologic
agent was conﬁrmed as Rhinocladiella similis, since it presented
sequence identity at 99% and coverage at 98% with the type strain of
this species (CBS 111763). This strain was added to GenBank as number
KY657562.
Due to the low eﬀectiveness of itraconazole observed in patient, the
absence of an antifungal test in the literature against this new agent of
chromoblastomycosis, and the existence of an in vitro antifungal activity
protocol, made available in 2008, the antifungal assay was evaluated
with the isolate. Therefore, the susceptibility assay was performed
according to the protocol M38-A2 of the Clinical and Laboratory
Standards Institute (CLSI), utilizing the microdilution technique [9].
For inoculum preparation, Rhinocladiella similis isolates were grown on
potato dextrose agar at 30 °C for 14 days. The colonies were covered
with approximately 3 mL 0.85% sterile saline solution, and a suspen-
sion was prepared by scraping across all colonies with a rigid sterile
plastic loop. The suspension was ﬁltered through a ﬁlter paper to
separate hyphae and conidia. Conidial-only presence in suspensions
was veriﬁed by microscopy, and the conidia quantitation was per-
formed with a Neubauer chamber [10]. The ﬁnal concentration in the
wells was 2.5×104 CFU/mL [9–11].
The following antifungals were evaluated: amphotericin B, itraco-
nazole, ketoconazole, voriconazole, posaconazole and terbinaﬁne (all
from Sigma-Aldrich, USA) in the ﬁnal concentration range of
0.03–16 μg/mL [9]. The incubation temperature was 35 °C for up to
ﬁve days [11]. The minimal inhibitory concentrations (MICs) were
determined when there was 100% of visual inhibition by comparing
antifungal concentration to the growth in the drug-free wells (growth
control) [9]. This assay was performed in triplicate.
After evaluating the MIC, the minimum fungicidal concentration
(MFC) was determined. A 50 µL aliquot from the wells in which no
growth was observed was transferred to a plate (1 mL 96-well type
plate) containing 800 µL/well of Sabouraud-dextrose broth. The plate
was incubated for 15 days at 30 °C and growth was visually observed.
MFC was deﬁned as the minimum concentration in which no fungal
growth occurred [12]. This assay was performed in duplicate.
The MIC obtained of antifungals were (µg/mL): posaconazole and
terbinaﬁne (0.5); itraconazole (1.0); ketoconazole and voriconazole
(2.0); amphotericin B (8.0). The MFC of posaconazole was 2.0 µg/mL
and for all the others, the MFC were ≥16.0 µg/mL.
3. Discussion
With the advent of molecular biology, it has been noticed that clade
Exophialia spinifera contains several morphologically similar species,
being Rhinocladiella similis one of them [4,13]. For many years, fungal
identiﬁcation was based on micro and macroscopic characteristics,
which led to a series of misidentiﬁcations, leading to under- or
overestimation of the number of infection cases caused by diﬀerent
species [4,5]. Currently, in research, the identiﬁcation based on
sequencing of the Internal Transcribed Spacer (ITS) region of ribosomal
DNA has been considered a reliable source of identiﬁcation for this
clade [13], but it has not been frequently used in clinical practices.
This is the ﬁrst report published in a scientiﬁc journal and the
second case published in the worldwide literature of Rhinocladiella
similis as chromoblastomycosis agent. The ﬁrst case was isolated before
2000 from the foot of a 72-year-old Caucasian male in Minas Gerais,
Brazil, and the report was presented at a scientiﬁc meeting (M.A.
Resende, R.B. Caligiorne, C.R. Aguilar and M.M. Gontijo, Abstr. 14th
Congr. Int. Soc. Human Anim. Mycol., p. 274, 2000). This isolate was
identiﬁed as R. similis in 2003 and it became the type strain for
comparison in Genbank (CBS 111763) [4]. The following species of the
genus Rhinocladiella have also been reported to relate to chromoblas-
tomycosis: R. aquaspersa, a classical chromoblastomycosis agent [1,2];
R. tropicalis, which was isolated from 4 Brazilians patients [1]; and R.
phaeophora, whose only report derives from a case in Thailand [14].
In the case presented herein, lesions were observed both on the foot,
a common site of chromoblastomycosis lesion, and in the chest, which
is less common. Typically, disease dissemination occurs slowly, with
continuous propagation around the infection source; in contrast,
noncontiguous or remote-site lesions may result from autoinoculation
caused by itching [2]. In this case, the primary lesion was on the foot,
whereas autoinoculation may have occurred on the chest, given the
distance to those lesions without lymphatic progression.
Using the cutoﬀ proposed by CLSI [9], the isolate was considered
sensitive to posaconazole and itraconazole. The isolate response was
characterized as intermediate to voriconazole and resistant to ampho-
tericin B. For terbinaﬁne and ketoconazole, there is no reference of
cutoﬀ in the protocol.
The MICs of posaconazole and voriconazole against R. similis were
similar to those of both antifungals against R. aquaspersa [10,15], and
Fig. 1. (A) Chest lesion caused by Rhinocladiella similis. (B) Sclerotic cells from a lesion sample observed by optic microscopy (400×). (C) Colonial morphology from R. similis in PDA after
incubation at 35 °C for 14 days.
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the MICs of ketoconazole, itraconazole, terbinaﬁne and amphotericin B
were similar to those against two other strains of the genus [11].
However, the R. similis isolate presented MICs 3-fold higher for these
last three antifungals, in comparison to R. aquaspersa, indicating that R.
similis may be less susceptible than R. aquaspersa to those antifungals.
This is an important observation because itraconazole is the standard
therapy for chromoblastomycosis [2]. Therefore, according to these
results, treatment with itraconazole may result ineﬀective or of
decreased eﬀectiveness when the infection is caused by R. similis.
Taking this into account, identiﬁcation at the species level of Rhinocla-
diella spp. and/or antifungal susceptibility assay should be performed in
clinical practices to avoid a treatment with low eﬀectiveness.
To our knowledge, the MFC test for Rhinocladiella genus causing
chromoblastomycosis had not been reported until now. For this isolate,
MFCs of the antifungals (except for posaconazole) were high, indicating
lower fungicidal activity against R. similis, which can make the
treatment diﬃcult if the patient is immunocompromised [12].
In this case, itraconazole was chosen as the initial treatment for the
patient in 2002 because it was and still is the standard medication
against CBM agents [2] and evaluating the in vitro antifungal test
performed in 2016, the isolate was considered sensitive to itraconazole,
since it was in the concentration range. Terbinaﬁne and posaconazole,
antifungals that have low MIC (both) and MFC (posaconazole), are
expensive drugs [2] for the patient's economic condition, therefore they
would not be used as treatment.
The duration of treatment with itraconazole is variable, but a range
from 8 to 10 months has been reported in many cases [2]. The patient's
follow-up occurred during the ﬁrst 8 months of treatment, and lesion
regression was observed. Unfortunately, after this period the patient
quit the treatment, returning 2 years later with active lesions which
were probably due to the intermittent and incomplete therapy. Thus, it
is impossible to inform if the treatment with itraconazole would be
eﬀective against R. similis if the patient had properly followed treat-
ment.
This report present R. similis as a new agent of chromoblastomycosis
and raise the hypothesis that this species could be more resistant to
some antifungals, such as itraconazole, than R. aquaspersa. In addition,
this article stress the importance of species-level identiﬁcation and
antifungal susceptibility testing in clinical practice.
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